Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribut

Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Charcot-marie-tooth (CMT) disease is caused by mutations in the genes that affect the structure and function of peripheral nerves that control movement and sensation. Defective genes can cause the nerve fibers (axons) or myelin sheaths (the fat layer that separates nerve fibers) to degenerate in the peripheral nerves. This weakens the transmission of nerve signals between the brain and limbs, causing muscle atrophy and decreased sensation. As charcot-marie-tooth disease progresses, symptoms will spread from the feet and legs to the hands and arms.
The severity of symptoms (that includes weakness in the legs, ankles, and feet, decreased muscle mass in the legs and feet, high foot arches, curled toes (hammer toes), and decreased walking and running ability, among others) varies from person to person, including between family members. The different types and subtypes of CMT are determined based on the mutant gene, genetic type, nerve conduction velocity, age of onset, disease severity, clinical symptoms, and peripheral nerve injury. The different types of CMT diseases include CMT1, CMT2, CMT3, CMT4, CMTX, and DICMT.
Market Dynamics
Increasing prevalence of charcot-marie tooth disease is one major factor driving the market growth. For instance, according to a data published by the Medscape in January 2021, the prevalence of CMT disease is one in 2,500 population, which is approximately 125,000 people in the U.S. The incidence of CMT 1 is 15 per 100,000 population; the incidence of CMT 1A is 10.5 per 100,000 population, or 70% of CMT 1. The incidence of CMT 2 is seven per 100,000 people. CMT X patients account for at least 10-20% of CMT syndrome patients.
Key features of the study:
This report provides in-depth analysis of the global charcot-marie-tooth disease market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global charcot-marie-tooth disease market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global charcot-marie-tooth disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global charcot-marie-tooth disease market
Detailed Segmentation:
Global Charcot-Marie-Tooth Disease Market, By Disease Type:
CMT 1
CMT 2
CMT 3
Others
Global Charcot-Marie-Tooth Disease Market, By Drug Type:
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
Global Charcot-Marie-Tooth Disease Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Charcot-Marie-Tooth Disease Market, By Region:
North America
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
CMT 1
CMT 2
CMT 3
Others
By Drug Type
Nonsteroidal anti-inflammatory drugs
Cyclooxygenase-2 inhibitors
Tricyclic antidepressants
Anticonvulsants
Analgesics
Pipeline Drug
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Addex Therapeutics Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Affectis Pharmaceuticals AG
Genzyme Corp
Lead Discovery Center GmbH
Pharnext SA
Acceleron Pharma
MedDay Pharmaceuticals
Bristol-Myers-Squibb Company
Inflectis Bio Science Health Company
Helixmith Co., Ltd.
Neurogene Inc.
“*” marked represents similar segmentation in other categories in the respective section.